Zenocutuzumab Side Effects
Applies to zenocutuzumab: intravenous solution.
General adverse events
The most common adverse events were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities were increased gamma-glutamyl transpeptidase (GGT), decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time (aPTT) and increased bilirubin.[Ref]
Hematologic
- Very common (10% or more): Decreased hemoglobin (35%), decreased platelets (26%), hemorrhage (up to 23%), decreased leukocytes (21%)
- Uncommon (0.1% to 1%): Myelodysplastic syndrome[Ref]
Immunologic
- Very common (10% or more): Infusion-related reactions (up to 13%)[Ref]
Infusion-related reactions (IRR) includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting.[Ref]
Musculoskeletal
- Very common (10% or more): Musculoskeletal pain (up to 28%)
- Common (1% to 10%): Traumatic fracture[Ref]
Metabolic
- Very common (10% or more): Decreased magnesium (up to 28%), increased alkaline phosphatase (up to 31%), decreased sodium (up to 28%), decreased phosphate (26%), decreased potassium (up to 26%), decreased appetite (up to 11%)[Ref]
Psychiatric
Oncologic
- Uncommon (0.1% to 1%): Tumor pain[Ref]
Respiratory
- Very common (10% or more): Dyspnea (18%), cough (15%)
- Common (1% to 10%): Interstitial lung disease/pneumonitis, respiratory failure
- Uncommon (0.1% to 1%): Upper respiratory infection, pneumonia[Ref]
Other
- Very common (10% or more): Fatigue (up to 21%), COVID-19 (up to 18%), edema (up to 13%), pyrexia (up to 10%)
- Uncommon (0.1% to 1%): Urinary tract infection, viral infection, sepsis, cellulitis, acute cholecystitis, lymphadenitis, staphylococcal infection[Ref]
Renal
- Common (1% to 10%): Increased creatinine
- Uncommon (0.1% to 1%): Acute kidney injury[Ref]
Cardiovascular
- Common (1% to 10%): Cardiac failure, Grade 2 LVEF
- Uncommon (0.1% to 1%): Tachycardia, pericardial effusion, cardiovascular fatal event, bradycardia, carotid artery stenosis[Ref]
Dermatologic
- Very common (10% or more): Rash (14%), dry skin (10%)[Ref]
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 36%), nausea (up to 23%), vomiting (up to 23%), abdominal pain (18%), constipation (15%), abdominal distension (13%), stomatitis (up to 10%)
- Uncommon (0.1% to 1%): Ascites, dysphagia, ileus, gastric obstruction[Ref]
References
1. (2024) "Product Information. Bizengri (zenocutuzumab)." Merus US, Inc
More about zenocutuzumab
- zenocutuzumab consumer information
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Zenocutuzumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.